Finance

Lists
INDV:NASDAQ
Indivior Pharmaceuticals Inc
၃၄.၁၁ US$
+၀.၇၁%
(+၀.၂၄) 1D
အောက် ၂၀, GMT-၄ ၀၉:၄၂:၅၄  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INDV...
Open
၃၄.၀၂ US$
High
၃၄.၁၆ US$
Low
၃၃.၈၀ US$
Mkt. cap
၄၀၂.၆၁ ဋေ
Avg. vol.
၂.၃၈ သန်း
Volume
၁.၇၅ ထောင်
P/E ratio
၁၂.၂၈
52-wk high
၄၂.၈၁ US$
52-wk low
၂၃.၉၉ US$
EPS
၂.၇၈ US$
Beta
၁.၁၀
Shares outstanding
၁၁.၈၀ ကုဋေ
No. of employees
၈၃၃
Open
၃၄.၀၂ US$
High
၃၄.၁၆ US$
Low
၃၃.၈၀ US$
Mkt. cap
၄၀၂.၆၁ ဋေ
Avg. vol.
၂.၃၈ သန်း
Volume
၁.၇၅ ထောင်
P/E ratio
၁၂.၂၈
52-wk high
၄၂.၈၁ US$
52-wk low
၂၃.၉၉ US$
EPS
၂.၇၈ US$
Beta
၁.၁၀
Shares outstanding
၁၁.၈၀ ကုဋေ
No. of employees
၈၃၃
News stories
From web sources and news partners
Indivior
Indivior
·
ပြီးခဲ့သည့် ၁ ရက်
Indivior to Report Third Quarter 2026 Financial Results
Simply Wall Street
Simply Wall Street
·
ပြီးခဲ့သည့် ၂ ရက်
Why Did Indivior Pharmaceuticals (INDV) Stock Slide And What Is Behind It?
Profile
Indivior is an American pharmaceuticals company. Established as a division of Reckitt Benckiser in 1994 and demerged from that company in December 2014, it is focussed on substitution products for opioid addiction. It is listed on the London Stock Exchange and on the NASDAQ Global Select Market. Wikipedia
About Indivior Pharmaceuticals Inc
CEOMark Crossley
Employees၈၃၃
Founded၂၀၁၄ စက် ၂၆
Headquarters-
Sector-
Analyst ratings
Based on 3 analysts giving stock ratings to INDV in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for INDV in the last 3 months.
Highest
Current ၃၄.၁၁ US$
၄၈.၀၀ US$ (+၄၀.၇၂%)
Average
၄၅.၅၀ US$ (+၃၃.၃၉%)
Lowest
၄၃.၀၀ US$ (+၂၆.၀၆%)
Analyst
Recommendation
Action
Price target
Projected
Date
Chase Knickerbocker
Craig-Hallum
Buy
Maintained
-
-
09/17/2026
Glen Santangelo
Barclays
Buy
Maintained
၄၃.၀၀ US$
+၂၆.၁%
08/05/2026
Brandon Folkes
H.C. Wainwright
Buy
Reiterated
၄၈.၀၀ US$
+၄၀.၇%
08/04/2026
David Amsellem
Piper Sandler
Buy
Reiterated
၅၉.၀၀ US$
+၇၃%
05/22/2026
Carl Byrnes
Northland Securities
Buy
Maintained
၅၀.၀၀ US$
+၄၆.၆%
02/27/2026
Last report
၂၀၂၆ ဩ ၃
Fiscal period
Q2 2026
၁.၁၅ US$ / ၀.၉၂ US$
+၂၄.၇၆%beat
Revenue / Est. (USD)
၃၄.၃၀ ကုဋေ / ၃၀.၇၆ ကုဋေ
+၁၁.၅၃%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၃၁.၄၀ ကုဋေ
၃၅.၈၀ ကုဋေ
၃၁.၇၀ ကုဋေ
၃၄.၃၀ ကုဋေ
Cost of goods sold
၄.၆၀ ကုဋေ
၅.၆၀ ကုဋေ
၄.၀၀ ကုဋေ
၄.၈၀ ကုဋေ
Cost of revenue
၄.၆၀ ကုဋေ
၅.၆၀ ကုဋေ
၄.၀၀ ကုဋေ
၄.၈၀ ကုဋေ
Research and development expenses
၂.၀၀ ကုဋေ
၁.၇၀ ကုဋေ
၉.၀၀ သန်း
၁.၂၀ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၁၃.၃၀ ကုဋေ
၁၅.၅၀ ကုဋေ
၁၂.၂၀ ကုဋေ
၁၂.၂၀ ကုဋေ
Operating expense
၁၅.၂၀ ကုဋေ
၁၆.၉၀ ကုဋေ
၁၃.၁၀ ကုဋေ
၁၃.၄၀ ကုဋေ
Total operating expenses
၁၉.၈၀ ကုဋေ
၂၂.၅၀ ကုဋေ
၁၇.၁၀ ကုဋေ
၁၈.၂၀ ကုဋေ
Operating income
၁၁.၆၀ ကုဋေ
၁၃.၃၀ ကုဋေ
၁၄.၆၀ ကုဋေ
၁၆.၁၀ ကုဋေ
Other non operating income
-၁.၀၀ သန်း
-
-
-
EBT including unusual items
၃.၇၀ ကုဋေ
၈.၁၀ ကုဋေ
၁၁.၅၀ ကုဋေ
၁၆.၀၀ ကုဋေ
EBT excluding unusual items
၁၀.၉၀ ကုဋေ
၁၃.၃၀ ကုဋေ
၁၄.၂၀ ကုဋေ
၁၆.၂၀ ကုဋေ
Income tax expense
-၅.၀၀ သန်း
-၂.၁၀ ကုဋေ
၂.၆၀ ကုဋေ
၃.၈၀ ကုဋေ
Effective tax rate
-၁၃.၅၁%
-၂၅.၉၃%
၂၂.၆၁%
၂၃.၇၅%
Other operating expenses
-၁.၀၀ သန်း
-၃.၀၀ သန်း
-
-
Net income
၄.၂၀ ကုဋေ
၁၀.၂၀ ကုဋေ
၈.၉၀ ကုဋေ
၁၂.၂၀ ကုဋေ
Net profit margin
၁၃.၃၈%
၂၈.၄၉%
၂၈.၀၈%
၃၅.၅၇%
Earnings per share
၀.၇၂
၀.၈၂
၀.၉၆
၁.၁၅
Interest and investment income
၆.၀၀ သန်း
၆.၀၀ သန်း
၃.၀၀ သန်း
၃.၀၀ သန်း
Interest expense
-၁.၂၀ ကုဋေ
-၆.၀၀ သန်း
-၇.၀၀ သန်း
-၂.၀၀ သန်း
Net interest expenses
-၆.၀၀ သန်း
-
-၄.၀၀ သန်း
၁.၀၀ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
၁၁.၉၀ ကုဋေ
၁၃.၅၀ ကုဋေ
၁၄.၈၀ ကုဋေ
၁၆.၃၀ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ